In February 2022, Alembic Pharma earned the highest moving annual revenue from its Anti-infective drug formulations Azithral, generating over 2.8 billion Indian rupees. The company's anti-infectives drug Althrocin and respiratory drug Wikoryl followed suite with over 842 million Indian rupees and 765 million Indian rupees respectively during the same time period.
Revenue of Alembic Pharma India in February 2022, by leading therapy drug (in million Indian rupees)
Basic Account
Get to know the platform
You only have access to basic statistics.
This statistic is not included in your account.
Starter Account
The ideal entry-level account for individual users
- Instant access to 1m statistics
- Download in XLS, PDF & PNG format
- Detailed references
$199 USD / Month *
Professional Account
Full access
Business Solutions including all features.
* Prices do not include sales tax.
Other statistics that may interest you Statistics on
About the industry
10
- Premium Statistic Growth rate of therapy drugs by Cadila Healthcare India 2022
- Premium Statistic Sun Pharma's revenue India 2022, by leading therapy drug
- Premium Statistic Revenue Cadila Healthcare India 2022, by leading therapy drug
- Premium Statistic Sun Pharma's market share of therapy drugs India 2022
- Basic Statistic Market share of generics in European countries 2021
- Premium Statistic Sawai Group's net income FY 2013-2022
- Premium Statistic Market share of therapy drugs by Cadila Healthcare India 2022
- Premium Statistic Sawai Pharmaceutical's total assets FY 2011-2020
- Premium Statistic Sawai's drug sales share in Japan FY 2018, by institution
- Premium Statistic Major drug manufacturers Japan 2017, by number of products
About the region
10
- Premium Statistic MAT of therapies in Indian pharma 2022
- Premium Statistic Distribution of therapies in Indian pharmaceuticals 2022
- Premium Statistic Growth rate of top therapies in Indian pharmaceuticals 2022
- Premium Statistic Dr. Reddy's Laboratories' PAT FY 2014-2023
- Premium Statistic Dr. Reddy's Laboratories' cash flow FY 2018-2023, by type
- Premium Statistic Aurobindo Pharma's revenue FY 2013-2023
- Premium Statistic Aurobindo Pharma's net debt to EBITDA ratio FY 2013-2023
- Premium Statistic Aurobindo Pharma's net debt to equity ratio FY 2013-2023
- Premium Statistic Aurobindo Pharma's EBITDA FY 2013-2023
- Premium Statistic Aurobindo Pharma's net profit FY 2013-2023
Other regions
10
- Basic Statistic Expenditure on pharmaceuticals in Sweden 2009-2023
- Premium Statistic Saving of U.S. costs through generic pharmaceuticals by condition 2022
- Basic Statistic Pharmaceutical sales value in Italy 2013-2022
- Premium Statistic Foreign-to-Canadian generic drug price ratios by OECD country as of 2018
- Premium Statistic Enterprise value of generic pharmaceutical companies with a U.S. presence 2016
- Premium Statistic Sawai Group's R&D expenditure FY 2013-2022
- Basic Statistic Washington D.C.'s medical cannabis spending 2018-2024
- Premium Statistic Venezuela: pharma industry market value 2008-2017
- Premium Statistic Peru's pharmaceutical and hygiene import value 2014-2018
- Premium Statistic Saudi Pharmaceutical Industries and Medical Appliances Corporation revenue 2012-2018
Related statistics
10
- Premium Statistic Aurobindo Pharma's revenue from U.S. formulations FY 2013-2023
- Premium Statistic Aurobindo Pharma's revenue from ARV formulations FY 2013-2023
- Premium Statistic Aurobindo Pharma's revenue from growth market formulations FY 2013-2023
- Premium Statistic Aurobindo Pharma's EBITDA margin FY 2013-2023
- Premium Statistic Aurobindo Pharma's revenue share 2023, by market
- Premium Statistic Aurobindo Pharma's expenditure on R&D FY 2017-2022, by type
- Premium Statistic Net profit of major pharma companies India 2024
- Premium Statistic Dr. Reddy's Laboratories' revenue FY 2017-2023, by product segment
- Premium Statistic Dr. Reddy's Laboratories' monthly share trade value at NSE FY 2023
- Premium Statistic Dr. Reddy's Laboratories' revenue FY 2014-2023
Further related statistics
8
- Pfizer's ad spending 2006-2023
- Sales of Johnson & Johnson 2006-2023 by region
- Foreign exchange earnings from tourism in India 2000-2022
- Number of international tourist arrivals in India 2010-2021
- International tourism receipts of India 2011-2022
- Per capita consumer spending in India 1974-2012
- M&A capacities - changes for the global pharma industry 2008-2015
- Number of patients with non-communicable diseases in India 2010
Further Content: You might find this interesting as well
Statistics
- Pfizer's ad spending 2006-2023
- Sales of Johnson & Johnson 2006-2023 by region
- Foreign exchange earnings from tourism in India 2000-2022
- Number of international tourist arrivals in India 2010-2021
- International tourism receipts of India 2011-2022
- Per capita consumer spending in India 1974-2012
- M&A capacities - changes for the global pharma industry 2008-2015
- Number of patients with non-communicable diseases in India 2010
Motilal Oswal Group. (March 8, 2022). Revenue of Alembic Pharma India in February 2022, by leading therapy drug (in million Indian rupees) [Graph]. In Statista. Retrieved May 15, 2024, from https://www.statista.com/statistics/1097049/india-alembic-pharma-revenue-by-leading-therapy-drugs/
Motilal Oswal Group. "Revenue of Alembic Pharma India in February 2022, by leading therapy drug (in million Indian rupees)." Chart. March 8, 2022. Statista. Accessed May 15, 2024. https://www.statista.com/statistics/1097049/india-alembic-pharma-revenue-by-leading-therapy-drugs/
Motilal Oswal Group. (2022). Revenue of Alembic Pharma India in February 2022, by leading therapy drug (in million Indian rupees). Statista. Statista Inc.. Accessed: May 15, 2024. https://www.statista.com/statistics/1097049/india-alembic-pharma-revenue-by-leading-therapy-drugs/
Motilal Oswal Group. "Revenue of Alembic Pharma India in February 2022, by Leading Therapy Drug (in Million Indian Rupees)." Statista, Statista Inc., 8 Mar 2022, https://www.statista.com/statistics/1097049/india-alembic-pharma-revenue-by-leading-therapy-drugs/
Motilal Oswal Group, Revenue of Alembic Pharma India in February 2022, by leading therapy drug (in million Indian rupees) Statista, https://www.statista.com/statistics/1097049/india-alembic-pharma-revenue-by-leading-therapy-drugs/ (last visited May 15, 2024)
Revenue of Alembic Pharma India in February 2022, by leading therapy drug (in million Indian rupees) [Graph], Motilal Oswal Group, March 8, 2022. [Online]. Available: https://www.statista.com/statistics/1097049/india-alembic-pharma-revenue-by-leading-therapy-drugs/